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Abstract  
Purpose:  Acute  exacerbation (AE) is  an important  outcome of  
idiopathic  pulmonary f ibrosis ( IPF) and nonspecific intersti t ial  
pneumonia  (NSIP).  Recombinant human soluble  thrombomodulin  
(rhTM) is  a  new drug for  the  t reatment  of  disseminate d int ravascular  
coagulat ion in  Japan.  The object ive  of  this  study was to  evaluate  the  
efficacy of  rhTM for AE of IPF/NSIP.  
Methods:  Twenty-two patients with AE -idiopathic intersti t ial  
pneumonia  (16 patients wi th IPF and six patients wi th NSIP) were  
enrol led in  our study.  Among them, eleven patients were t reated with  
rhTM (rhTM group),  and e leven pat ients were  t reated wi thout  rhTM 
(non-rhTM group). Patients admitted to our  hospital  prior  to  December 
2013 were  t reated with rhTM, whi le  those  admit ted af ter  Jan uary 2014 
were  t reated without rhTM. The primary endpoint  was mortali ty a t  90  
days after  AE t rea tment .  The secondary endpoint  was the  safety of  
rhTM for  AE-IPF/AE-NSIP.  In  addit ion,  we examined prognost ic  
factors of AE-IPF/AE-NSIP.  
Results:  The mortali ty ra te was signif icantly lower in the rhTM group 
than in the non-rhTM group (mortali t y ra te a t  90 days : 36% vs 90%, 
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P=0.023;  median survival t ime: not  reached vs 15.0 days,  P=0.019) .  A 
univariate  analysis  revealed the respiratory ra te (hazard rat io  [HR] 1.09,  
95% confidence  interval  [CI]  1.00–1.18,  P=0.039)  and rhTM 
administration (HR 0.21,  95% CI 0.06 –0.77,  P=0.013) as predic tors of  
mortal i t y at  90 days,  and a multivar iate analysis  ident if ied rhTM 
administration (HR 0.025,  95% CI 0.0006 –0.94,  P=0.046)  as an 
independent  predic tor of mortal i ty at  90 days.  No ser ious adverse  
events were  observed.  
Conclusion:  The administ ra tion of rhTM is associated with reductions  
in  morta li t y in  patients with AE -IPF/NSIP,  without  causing adverse  
events.  
Keywords:  recombinant  human soluble  thrombomodul ine ,  acute  
exacerbation, idiopathic pulmonary fibrosis , nonspecif ic intersti t ial  
pneumonia  
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Introduction 
Acute  exacerbation (AE) was f irst  descr ibed in patients with 
idiopathic  pulmonary fibrosis  ( IPF). 1 )  AE is  an important complica t ion 
in  patients wi th IPF.  The incidence rate  of  AE -IPF at  1 year  i s  14.2%, 2 )  
and the  outcomes of  AE -IPF are  very poor,  wi th reported mortali t y ra tes 
at  1 month and 3 months of ~60% and ~67%, respectively. 3 )  Patients 
wi th nonspecific  interst i t ial  pneumonia  (NSIP) have also been reported 
to  develop AE, and the  incidence  rate of AE -NSIP a t 1 year  i s  4 .2%. 4 )  
Usui et  al  reported that , in thei r re trospective  analysis , the  survival rate  
of  AE among patients wi th chronic fibrosing interst i t ial  pneumonia 
(including IPF,  NSIP,  and chronic hypersensit ivity pneumonia)  was 
67% at  30 days,  43% at  60 days,  and 40% at  90 days in  51 patients. 5 )  In  
general , high-dose corticosteroid therapy is  often administered to  
pat ients with AE-IP F,  al though there  is currently insufficient  evidence 
regarding the  usefulness of  corticosteroid t rea tment  in  these  cases.  
Furthermore , while some authors have reported the  eff icacy of  
immunosuppressive agents (ie ,  cyclosporine  A), 6 )–8 )  there  i s  no 
evidence to  support  this observation at  present.  
Recombinant  human soluble  thrombomodulin (rhTM) 
(Recomodulin®;  Asahi  Kasei  Pharma Corporation, Tokyo,  Japan) i s a 
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transmembrane prote in expressed on the  endothelial  cell  surface,  which 
plays an important  role in the  regulation of intravascular  coagulation. 9 )  
In  Japan,  rhTM has been approved for the  t rea tment  of  disseminated 
int ravascular  coagulation (DIC).  Thrombomodulin has an 
ant icoagulation and an anti -inf lammatory effec t, 9 ) ,1 0 )  and Ogawa et  a l  
reported that , in  86 patients with sepsis -induced DIC who required 
mechanical venti lator  management , rhTM administ rat ion had a  
signif icant  beneficia l  effec t on both mortali ty and respiratory 
dysfunction.11 )  Recently,  there have been t ria ls of  the  administ rat ion of  
rhTM in patients wi th AE -IPF/NSIP;  however,  the  efficacy of this drug 
remains unclear.  Therefore , the purpose  of  this  study was to  
prospect ively compare  and analyze cl inica l data for  patients wi th 
AE-IP F/NSIP in order  to evaluate  the  eff icacy of  rhTM in this 
populat ion.  
 
Material  and Methods  
This study was a single -center prospect ive study.  The research 
protocol  was approved by the Human Ethics Committee of Chiba 
Universit y Hospita l ,  and informed consent  was  obtained from all  
pat ients and thei r family members. The t rial  registra tion number is  
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UMIN000012590.  
 
Patients  
Between October 2012 and Augus t 2014, 46 pat ients suspected 
of  having an AE of  intersti t ia l  pneumonia  were  treated a t  Chiba  
Universit y Hospital  (Figure 1).  Five  patients with collagen vasculi t i s  
syndrome-re lated IP,  three pat ients wi th drug -induced IP,  three pat ients 
wi th eosinophi lic  pneumonia,  three  pat ients wi th acute  intersti t ial  
pneumonia , one patient with radia tion pneumonia , and one patient with  
hypersensit ivity pneumonia  were  excluded.  Four  patients with 
complicat ions re lated to lower respiratory pneumonia and four  patients  
diagnosed with DIC on admission were  excluded.  The Japanese  
Associa tion for Acute Medicine  DIC scoring system was used to  
identi fy DIC in patients. 12 )  
 
Diagnosis of  IPF and NSIP 
The diagnosis of  IPF was made according to  the  2011 
ATS/ERS/JRS/ALAT guidelines. 1 3 )  The high-resolution computed 
tomography (HRCT) fea tures of  NSIP include the  following: 1) bilateral  
ground-glass areas in  the  lungs,  sometimes wi th an ext ensive 
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dist ribution; 2) ret icular opacity,  which may be  superimposed on a 
ground-glass pat tern; and 3) traction bronchiectasis , which may be 
parallel  in course through the  lungs or  extremely i rregular . 1 4 )  Enrolled 
pat ients clinically diagnosed with connecti ve  t i ssue  disease were  
excluded.  
 
Diagnosis of  AE 
The diagnosis of  AE was based on the cr iteria  proposed by 
Kondoh et  a l . 1 )  These  cr iteria  contain four  condi tions : 1) onset  of  
exacerbation of  dyspnea within a  few weeks, 2) newly developing 
di ffuse  pulmonary infil tra tes on chest  X-ray f ilms, 3) .10 mmHg 
decreases in  oxygen partia l  pressure  (PaO 2 ) in  the  resting arterial  blood 
compared to  the  previous measurements,  and 4)  the  absence  of  an 
apparent infectious agent . Collard et  al  suggested that the  findings of 
HRCT comprise  new bi latera l ground-glass abnormali t ies and/or  
consol idation superimposed on a  background reticular  or  honeycomb 
pat tern, consistent with the  usual intersti t ia l  pneumonia pat tern. 15 )  
In  order to  exclude cases of  infect ion,  we examined sputum 
and/or  bronchoalve olar  lavage (BAL) cultures in  al l  cases. In  addit ion,  
we examined the  levels of  urinary ant igens for  Streptococcus pneumonia  
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and Legionella pneumophilia  serotype 1, antigens for influenza A and B 
vi ruses using pharyngeal swabs,  antigenemia  for  cytomegalovi rus,  and 
serum antigens for  Aspergillus .  Moreover,  we excluded other  alternative  
etiologies,  including left  heart  failure,  pulmonary embol ism, and 
identi fiable  causes of acute  lung injury. 1 5 )  
 
Laboratory  data  
The fol lowing parameters were measured on the  f irst  day of 
admission (day 1) and days 3 and 8 after  admission: white  blood cel l  
(WBC) count  and the  levels of  fibrinogen degradation products (FDP, 
normal range: <5 mg/mL),  d -dimer (normal range: <1 ng/mL),  
thrombin–anti thrombin complex (normal range: <4 ng/mL),  
plasmin–alpha 2-plasmin inhibitor  complex (normal  range: <0.8 mg/mL),  
C-reactive  prote in (CRP,  normal  range: <0.3 mg/dL),  serum lactate  
dehydrogenase  (LDH, normal range: 120 –235 IU/L),  brain natr iuret ic 
peptide  (normal  range: 20 pg/mL),  Krebs von den Lungen -6 (KL-6,  
normal range: <500 U/L),  and surfactant  protein -D (normal range: <110 
ng/mL).  
 
Treatment s trategy for AE-IIP 
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The t rea tment  st rategy was determined before the  star t  of  the  
study as fol lows. The patients with AE -IPF/NSIP enrolled between 
October 2012 and December 2013 were  administered rhT M (rhTM 
group),  and the  pat ients with AE -IPF/NSIP enrolled between January 
2014 and December 2014 were  not  administered rhTM (non -rhTM 
group).  The patients were  t rea ted wi th methylprednisolone pulse  
therapy ( intravenous administ ration of 1 g of  methylpredn isolone for  3  
days)  and maintenance therapy with  corticosteroids. We recommended 
immunosuppressive agents (ie ,  cyclophosphamide and/or  cyclosporine) 
to  be  administered in  patients with AE -IPF/NSIP,  except  for the 
super-elderly (>81 years)  individuals with a  poor  general  condi tion and  
individuals who demonstrated a  signif icant  improvement wi th the  
ini tial  t reatment .  
In  the  rhTM group, 0 .06 mg/kg/d of  rhTM (diluted in  100 mL of  
steri le  sal ine)  was administered intravenously for  30 minutes over  the 
fi rst  6  days. 1 1 )  
Oxygen therapy was administered to  keep the PaO 2  va lue >60 
mmHg (corresponding to a SpO 2  of  90%). We first  chose nonposit ive  
pressure  ventilation therapy.  If  the PaO 2  value  was not  mainta ined >60 
mmHg, the  pat ient  was t rea ted wi th noninvasive  positive  pr essure 
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ventilation or high -f low nasal  oxygen therapy.  Whether invasive  
mechanical  vent ila tion was performed was determined by respecting the  
intent ions of  the patient  and his/her  family members.  
 
Endpoints  
The primary endpoint was mortal i ty at  90 days after t reatment  
for  AE-IPF/NSIP.  The secondary endpoint  was the  safety of  rhTM in  
pat ients with AE-IPF/NSIP.  
 
Statistical  Analysis.  
The cl inical  data  are expressed as the  mean ± SD. We compared the  two 
groups using the  Mann–Whitney U-test  for  cont inuous variables and  
using the  Fisher ’s exact  test  for  categorical  var iables.  A Kaplan –Meier  
model  was genera ted to  evaluate survival ra te . Univaria te and 
mul tivar iate analyses were  performed based on Cox regression  
modeling.  A multivaria te analysis  of mortal i t y a t  90 days was  
performed using variables that  are  found to exhibit  a  signif icant  
difference  in  the  univaria te  analysis  in addit ion to variables with a  
signif icant  difference  between the groups on admission (WBC and 
KL-6) . Al l  sta ti st ical  analyses were performed using the  EZR Software  
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package (Sai tama Medical Center, J ichi  Medical Universit y,  Sai tama,  
Japan) , 16 )  a graphical  user  interface  for R (The  R Formulation for  
Sta tist ica l Comput ing Version 3.0.3).  Statistica l significan ce was  
defined as a  P -value of <0.05.
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Results  
Study  population  
Sixteen pat ients with AE -IPF and six patients wi th AE -NSIP 
were  enrol led in  this  study.  Six patients with AE -IPF were  diagnosed 
based on the  presence  of  usual intersti t ia l  pneumonia pat tern on a  
surgical  biopsy.  The remaining ten patients  wi th AE-IPF were 
diagnosed based on the  f indings of chest HRCT, excluding other  
different ial  diagnoses. Six patients with AE -NSIP were  diagnosed 
based on the findings of HRCT, excluding other di fferent ial  diagnoses. 
As shown in Figure  1,  eleven patients with AE -IPF/NSIP were  
administered rhTM (rhTM group),  and the  other  eleven patients wi th 
AE-IP F/NSIP were  not  administered rhTM (non -rhTM group).  The 
basel ine values in  the two groups (rhTM group and non -rhTM group) 
are  shown in Table  1.  There were  no significant  di fferences between the  
two groups in  terms of  age , sex,  cl inical  diagnosis of  IPF/NSIP,  
administration of  prednisolone or immuno suppressants prior  to AE,  
physical  examination findings,  sequent ial  organ fa ilure  assessment  
score,  acute physiology and chronic health evaluation II score,  and 
PaO2 /FIO 2 .  The WBC and KL-6 values were  significantly higher in  the  
rhTM group than those  in  th e non-rhTM group (P=0.047 and P=0.033,  
13 
respect ively) . The other laboratory data did not  show any signif icant 
differences between the  two groups.  
Therapeutic interventions,  outcomes,  and causes of  death are 
shown in Table 2.  There  were  no significant  differe nces in  the 
therapeutic interventions between the  two groups.  A tota l  of e ight  
pat ients (six  patients in the rhTM group and two patients in the 
non-rhTM group,  P=0.20)  underwent  BAL using bronchoscopy.  Lower 
respiratory tract  infect ions were excluded based  on the results  of  
cul ture  examinations of  BAL f luid and/or sputum. Furthermore , we 
examined urinary antigens for  S. pneumonia  and L.  pneumophil ia  
serotype 1,  antigens for  influenza A and B vi ruses using pharyngeal 
swabs,  ant igenemia  for cytomegalovirus,  a nd serum antigens for  
Aspergillus .  There  were  no patients with suggested infection.  
 
Effect  of  rhTM on mortali ty  
The mortal i t y rate at  30 days af ter  t reatment  was not  
signif icant ly di fferent  between the  rhTM and non-rhTM groups (18% vs  
54%, P=0.18) . In  contrast ,  the morta li t y at  90 days after treatment  was 
signif icant ly lower in  the  rhTM group than  in  the  non-rhTM group  (36% 
vs 90%, P=0.023) . The cause of  death included respiratory fa ilure  in 10 
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pat ients in the  non-rhTM group, whereas three  of four pat ients died due 
to  respira tory fai lure  and one pat ient  died due to  drug-induced hepatic  
fai lure and renal fai lure  in  the  rhTM group.  The survival curve s for  the  
two groups determined according to the  Kaplan-Meier  analysis  are  
shown in Figure 2.  The median survival  t ime (MST) was 14 days in the  
non-rhTM group.  
 
Effects of  rhTM on the c linical data  
The CRP, LDH, PaO2 /FIO2  and FDP values were  compared 
between the  two groups on the  first  day o f  admission (day 1)  and day 8 
(Figure  3) . The level s of CRP, LDH and FDP were  signif icant ly 
decreased in the rhTM group compared to  those  observed in  the  
non-rhTM group.  Although we a lso compared the laboratory data  
obtained on day 3, we were  unable  to confirm a  tendency toward  
improvement  in the  rhTM group.  
 
Prognostic factor s 
The univariate  analysis  revealed rhTM  administ rat ion  (HR 0.21, 
95% confidence  interval  [ CI]  0 .06-0.77, P=0.013)  as predic tors of 
mortal i t y at  90 days (Table  3) . Meanwhile ,  the  multivaria te  analysis  
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identi fied  rhTM administration  (HR 0.17,  95% CI 0.034-0.88,  P=0.035)  
to  be  an  independent  predic tor of mortal i t y at  90 days  (Table 4 ).   
 
Adverse  events  
One pat ient in  the rhTM group died due to  hepatic and renal  
fai lure  31 days af ter  admission.  Due to the  interaction of  warfarin 
administered to  t rea t at rial  fibr il lation,  i t  was difficul t  to  control the  
pat ient’s blood cyclosporine conce ntra tion. Therefore , we suspected 
that the  adverse  event  was due to  the  high concentration of  
cyclosporine . The patient developed hepatic and renal failure 24 days  
after the last  administ rat ion of  rhTM, and we thus consider no  
rela tionship between the adve rse event  and rhTM in this case . There  
were  no other  adverse  events in this  study.
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Discussion 
This prospect ive  study showed that int ravenous rhTM treatment  
has the  potent ial  to  improve outcomes in  pat ients with AE -IPF/NSIP.  In  
particular,  the  univariate  and mul t ivaria te  analyses revealed the 
eff icacy of rhTM. We propose that  the discrepancy in the survival  ra tes 
between the  two groups was due to the  administration of rhTM, as the  
therapeutic st ra tegy and ini tial  data,  other  than the  WBC and KL -6 
levels,  were  not  signifi cant ly different between the two groups.  
Kubo et  al  reported that  disorders of  coagulat ion and 
fibrinolysis  are  important  components of  AE -IPF and that  anticoagulant  
therapy for AE-IPF is  effic ient. 1 7 )  However, Noth et  al  reported that  
trea tment  wi th warfari n in patients with progressive  IPF was found to 
be  associa ted wi th an increased risk of morta li t y in  a  double -blinded,  
randomized,  placebo -controlled t rial . 18 )  
The rhTM is an intravenous therapeut ic agent against acute  DIC 
in Japan and has effects  to improve  the  burst  of coagula tion systems. 
Recent ly,  there have been reports  indicating that  the  levels of serum 
coagulat ion factors are  higher in  patients with AE -IPF than in patients 
wi th IPF. 1 9 )  20 )  We suppose  that  these data show pathological ly 
localized coagula t ion disturbance in  the parenchymal  lung lesions of  
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pat ients with AE-IPF/NSIP.  Tsushima e t al  also reported that the  
administration of  rhTM improves activated coagulat ion disturbances 
and that the morta li t y ra te  at  28 days is significantly lower in AE -IPF 
pat ients treated with rhTM than in  those  t reated without  rhTM. 19 )  In  
this  study,  the CRP, LDH, and FDP values on day 8 decreased 
signif icant ly in the rhTM group.  This finding suggests tha t the  
administration of  rhTM may improve disturbances of coagula tion an d a  
hyperinf lammatory sta te.  Therefore,  rhTM administ ra tion is  useful  for  
AE sta tus in  IPF/NSIP -patients wi th disturbances of  coagulation 
system.  
Thrombomodul in plays an important  role  in  regula ting both 
coagulat ion and inf lammation.  1)  Thrombomodul in binds  to thrombin 
and inhibits  ac tivity of  thrombin.  2)  The protein C,  which is  activated 
by the  thrombin– thrombomodulin complex, inhibits  coagulant  ac tivi ty.  
3)  The act ivated protein C has an ant i -inflammatory effect  by 
downregulating the  expression of  inflamm atory cytokines,  such as 
tumor necrosis factor -alpha. 2 1 )  2 2 )  4)  Thrombomodulin has another 
mechanism underlying the  anti -inf lammatory effec ts,  ie,  the  N -terminal  
lectin-like  domain of thrombomodulin inact ivates sequesters 
high-mobili ty group box -1 protein (HMGB-1),  which is re leased from 
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necrotic  ce lls  and subsequently causes cel l  damage. 2 3 )  Deng et  al  
reported that  HMGB-1 activates alveolar macrophages to  produce 
proinf lammatory cytokines and induce acute  lung injury. 24 )  In  addi tion,  
a previous report  showed t hat  the  serum HMGB-1 levels are  
signif icant ly lower in  survivors than in  nonsurvivors. 1 9 )  Therefore,  the  
ant i -inflammatory activity of  rhTM is considered to  be  an important 
factor for  the  mortali ty of  AE -IPF.  In this study,  the  serum CRP levels 
improved more significant ly in  the rhTM group than in  the  non -rhTM 
group (Figure  3).  
In  the  non-rhTM group,  the  MST was 14 days.  This i s shorter  
than that  noted in the previous reports. 3 )  5 )  The officia l  
ATS/ERS/JRS/ALAT statement  recommends that  the majorit y of 
pat ients with respiratory failure due to  IPF should not  receive 
mechanical venti lat ion. 1 4 )  Therefore , in  this  study,  no pat ients were 
trea ted using invasive  mechanical  ventilation.  In  the  patients in  whom 
it  was not possible  to mainta in the  blood concentrat ion of o xygen wi th 
noninvasive  vent ila tion, we primarily offered t reatment  to rel ieve  their  
discomfort  and dyspnea with drugs such as morphine.  Morphine also 
has an effect  in  inducing respiratory suppression.  For this reason,  the 
MST was shorter in  the  non -rhTM group than in  the  previous reports .  
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This study is  associa ted wi th several  l imitations.  Fi rst ,  this 
study was a single -center, nonrandomized prospective  study.  Therefore ,  
the  background fac tors of the two groups were  slightly di fferent.  In  
particular,  the  WBC a nd KL-6 levels on admission were  significantly 
higher  in the  rhTM group than in the non -rhTM group. We suppose  that  
these  di fferences on admission did not  inf luence the prognosis of  the  
two groups,  as high WBC and KL-6 levels are not  thought  to  be good 
prognostic fac tors in general . We therefore  conducted a multivaria te  
analysis  including different  fac tors ident ified  in  the  univariate  analysis  
as wel l  as the  WBC and KL-6 levels.  Second, the number of  patients 
was too small .  For this reason,  some differences between the  two 
groups at  the  t ime of  hospita lization were  observed,  al though not  
signif icant . For  instance , the age of  the pat ients in the rhTM group was  
less than those in  the  non -rhTM group (68.9±7.3 years vs 73.1±11.3 
years,  respect ively,  Table  1) .  Thi rd,  we were  unable  to  confi rm the 
existence  of microvascular thrombus formation in  the  lungs of the 
pat ients with AE-IPF/NSIP pathological ly.  It  i s necessary to clari fy the  
effects  of  rhTM on the  pathophysiology of AE -IPF/NSIP.  Fourth, s ince 
corticosteroids were administered in  all  cases and the  levels of  
inflammatory markers other  than CRP (eg,  HMGB -1) were  not  measured, 
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we were unable to  sufficiently evaluate the  anti -inflammatory effects  of  
rhTM. 
 
Conclusion  
The administ ration of  rhTM is associa ted with reductions in  
mortal i t y in  patients with AE -IPF/NSIP.  In order  to  confirm this  finding,  
a large-scale , prospective , randomized, double -blinded study is needed.  
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Figures  
Figure 1 . Flow diagram of patient s with acute  exacerbat ion .  
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Figure 2.  The survival  curve  of  11 patients wi th acute exacerbation 
who t rea ted rhTM, and 11 patients who treated without rhTM.  
AE-IIP;  acute excerbation of  idiopathic intersti t ial  pneumonia ,  rhTM; 
recombinant  human thrombomodu l ine  
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Figure 3. The serial  changes in the cl inica l data between AE-IPF/NSIP 
pat ients treated with rhTM (rhTM group) and without  rhTM (non -rhTM 
group).  Serum CRP, serum LDH and plasma FDP were decreased 
signif icant ly in rhTM group.  CRP: C-reactive protein,  FDP: f ibrinogen 
degradation products,  LDH: serum lacta te  dehydrogenase,  rhTM; 
recombinant  human thrombomodul ine . Wilcoxon’s signed rank test .  *;  
P<0.05 
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Table 1.  Baseline characteristics of the  pat ients on admission  
 
 
Table  2 . Therapeut ic  interventions,  outcomes,  and cause  of  death of  the  
pat ients  
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Table 3.  Univariate analysis  of survival  
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Table 4.  Mult ivar iate  analys is  of  survival  
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